Table 2.

Incidence of AEs.

Adverse event	All patients (N = 199)
Any treatment-emergent AE	189 (95.0)
Treatment-emergent serious AEa	35 (17.6)
Treatment-emergent AE leading to permanent treatment discontinuation	1 (0.5)
Deathb	4 (2.0)

AE: adverse event.

Data are n (%) of patients.

^a One myocardial infarction occurred approximately 8 months after the first alemtuzumab course and no strokes or arterial dissections were reported.

^b Causes of death were unknown (n = 1); suicide (n = 1); severe acute kidney injury, febrile neutropenia, metabolic encephalopathy, and pancytopenia 14 months after starting treatment with alemtuzumab (n = 1; pancytopenia was deemed related to alemtuzumab treatment by the investigator); and multiple sclerosis complications 20 months after starting treatment with alemtuzumab (n = 1; deemed unrelated to alemtuzumab treatment by the investigator).